Accretion Pharmaceuticals Ltd
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
- Market Cap ₹ 67.6 Cr.
- Current Price ₹ 60.8
- High / Low ₹ 83.0 / 57.4
- Stock P/E 9.96
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 46.4 %
- ROE 65.4 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 116 to 74.2 days.
- Company's working capital requirements have reduced from 127 days to 65.3 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 13.35 | 57.38 | |
| 10.78 | 45.49 | |
| Operating Profit | 2.57 | 11.89 |
| OPM % | 19.25% | 20.72% |
| 0.05 | 0.09 | |
| Interest | 0.40 | 1.44 |
| Depreciation | 0.22 | 0.77 |
| Profit before tax | 2.00 | 9.77 |
| Tax % | 25.00% | 30.40% |
| 1.49 | 6.79 | |
| EPS in Rs | 3.72 | 8.31 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 330% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 356% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 65% |
Balance Sheet
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 4.00 | 8.17 |
| Reserves | 1.49 | 7.12 |
| 13.48 | 14.10 | |
| 8.47 | 10.48 | |
| Total Liabilities | 27.44 | 39.87 |
| 5.25 | 6.09 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 |
| 22.19 | 33.78 | |
| Total Assets | 27.44 | 39.87 |
Cash Flows
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -11.51 | 5.75 | |
| -5.48 | -1.61 | |
| 17.08 | -4.18 | |
| Net Cash Flow | 0.09 | -0.04 |
Ratios
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 158.58 | 74.17 |
| Inventory Days | 564.06 | 188.49 |
| Days Payable | 256.32 | 69.41 |
| Cash Conversion Cycle | 466.31 | 193.25 |
| Working Capital Days | 189.47 | 65.33 |
| ROCE % | 46.36% |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
23 September 2025 - Accretion Pharmaceuticals canceled participation in Arihant Bharat Connect virtual conference on 23 Sept 2025 at 4:00 PM.
-
Press Release
22 September 2025 - Received Malawi PMRA cGMP approval for two years enabling direct exports, expected to boost FY26 revenue.
-
General Updates
19 September 2025 - Accretion Pharmaceuticals received cGMP approval from Malawi, valid two years, enabling direct exports (19 Sep 2025).
-
Analysts/Institutional Investor Meet/Con. Call Updates
15 September 2025 - Management to participate in Arihant Bharat Connect Virtual Conference on 23 Sept 2025.
-
Updates
5 September 2025 - AGM on 25 Sep 2025; Annual Report FY2024-25 available online; shareholder email not registered.
Business Profile[1]
The company manufactures pharmaceutical formulations, including both generic and branded products. It offers contract and third-party manufacturing services for domestic and international markets. Its clientele includes private institutions, government sectors (state and central), and reputed pharmaceutical companies.